Core Viewpoint - The approval of the clinical trial for the biosimilar Y225 marks a significant advancement for the company in the treatment of Hemophilia A, potentially filling a gap in the domestic market for high-barrier bispecific monoclonal antibody biosimilars [1][2] Group 1: Product Development - The clinical trial for Y225, a biosimilar to the drug Shuyou Lile® (Emicizumab injection), has been approved by the National Medical Products Administration (NMPA) of China, with the trial set to begin on December 23, 2025 [1] - Y225 is designed to treat Hemophilia A, a condition caused by a deficiency in coagulation factor VIII, which leads to bleeding disorders [1] - The original drug Shuyou Lile® is the only bispecific antibody approved for preventive treatment in patients with or without factor VIII inhibitors, but its high cost limits patient access [1] Group 2: Competitive Advantage - The company has innovatively overcome the formulation patent of the original drug, allowing Y225 to potentially launch seven years earlier than expected, making it the first biosimilar of Shuyou Lile® to enter the domestic market [1] - The existing patents for Shuyou Lile® extend its protection until 2038, creating a significant barrier to entry for competitors [1] Group 3: Strategic Partnerships - A strategic cooperation agreement was signed with Hubei Jiangxia Laboratory on June 17, 2025, to leverage the laboratory's research capabilities alongside the company's experience in antibody drug development [2] - The collaboration will focus on innovative antibody molecule design, efficient production process development, and clinical research, with Y225 as the first project [2] - This partnership aims to enhance the overall research and development efficiency and long-term industrialization potential of the company's pipeline [2]

Core Viewpoint - Youzhiyou Biotech-B (02496.HK) has received approval from the National Medical Products Administration (NMPA) of China for the clinical trial application of its biosimilar Y225, aimed at treating Hemophilia A [1][2] Group 1: Product and Market Potential - Y225 is a biosimilar of the dual-specific antibody Shuyou Lile® (Emicizumab injection), which targets FIX and FX for the treatment of Hemophilia A [1] - The original drug Shuyou Lile® is the only dual antibody medication available for preventive treatment in patients with or without factor VIII inhibitors, offering advantages such as once every four weeks dosing and subcutaneous injection [1] - The high cost of Shuyou Lile® limits patient access, and over 20% of Hemophilia A patients develop inhibitors that affect treatment efficacy [1] - The original drug has a patent protection period extended to 2038, but the company has innovatively overcome the formulation patent, allowing Y225 to potentially launch seven years earlier, filling a gap in the domestic market for high-barrier biosimilars [1] Group 2: Clinical Trial Details - The approved clinical trial is a randomized, double-blind, single-dose, parallel-comparison study assessing the bioequivalence of Shuyou Lile® and Y225 in healthy male subjects [2] - The trial is led by Dr. Huang Chaolin from Wuhan Jinyintan Hospital as the principal investigator [2]